Advertisement

Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma

  • Naoto FujitaEmail author
  • Ryoji Kobayashi
  • Yoshiko Atsuta
  • Fuminori Iwasaki
  • Junji Suzumiya
  • Yoji Sasahara
  • Masami Inoue
  • Katsuyoshi Koh
  • Tsukasa Hori
  • Hiroaki Goto
  • Tatsuo Ichinohe
  • Yoshiko Hashii
  • Koji Kato
  • Ritsuro Suzuki
  • Tetsuo Mitsui
Original Article
  • 24 Downloads

Abstract

We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. 55%; P = 0.036). Multivariate analysis of survival rates identified allogeneic graft, Burkitt histology, and lack of response to chemotherapy as poor prognostic factors for survival. The cumulative incidence of treatment-related mortality (TRM) was significantly higher in allo-HSCT compared to auto-HSCT recipients (P = 0.017), explaining the difference in survival rates. In patients with Burkitt lymphoma (BL), overall survival was significantly inferior in the group of patients undergoing HSCT within 12 months from the initial diagnosis (P = 0.039). These data indicate that treatment outcomes for HSCT in children and adolescents with B-NHL were better in autograft recipients, suggesting that greater attention should be paid to the risk of TRM, especially after allografts, for patients with BL.

Keywords

Lymphoma Childhood B-NHL Hematopoietic stem cell transplantation 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Minard-Colin V, Brugières L, Reiter A, Cairo MS, Gross TG, Woessmann W, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33:2963–74.CrossRefGoogle Scholar
  2. 2.
    Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmerman M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin–Frankfurt–Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294–306.Google Scholar
  3. 3.
    Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphoma and L3 leukemia. Blood. 2001;97:3370–9.CrossRefGoogle Scholar
  4. 4.
    Bradley MB, Cairo MS. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant. 2008;41:149–58.CrossRefGoogle Scholar
  5. 5.
    Fujita N, Mori T, Mitsui T, Inada H, Horibe K, Tsurusawa M. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer. 2008;51:188–92.CrossRefGoogle Scholar
  6. 6.
    Bureo E, Ortega JJ, Muñoz A, Cubells J, Madero L, Verdaguer A, et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 1995;15:353–9.Google Scholar
  7. 7.
    Giulino-Roth L, Ricafort R, Kernan NA, Small TN, Tripett TM, Steinherz PG, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013;60:2018–24.CrossRefGoogle Scholar
  8. 8.
    Jourdain A, Auperin A, Minard-Colin V, Aladjidi N, Zsiros J, Coze C, et al. Outcome and prognostic factors of relapse in children and adolescents with mature B-cell lymphoma and leukaemia treated in 3 consecutive prospective lymphomes malins B protocols. Study of the Societe Francaise des Cancers de l’Enfant. Haematologica. 2015;100:810–7.CrossRefGoogle Scholar
  9. 9.
    Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16:223–30.CrossRefGoogle Scholar
  10. 10.
    Okur FV, Krance R. Stem cell transplantation in childhood non-Hodgkin’s lymphoma. Curr Hematol Malig Rep. 2010;5:192–9.CrossRefGoogle Scholar
  11. 11.
    Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Besien KV, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003;101:2476–82.CrossRefGoogle Scholar
  12. 12.
    Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M. Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer. 2009;52:591–5.CrossRefGoogle Scholar
  13. 13.
    Woessmann W, Peters C, Lenhard M, Burkhardt B, Sykora KW, Dilloo D, et al. Allogeneic hematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents: a Berlin–Frankfurt–Munster group report. Br J Haematol. 2006;133:176–82.CrossRefGoogle Scholar
  14. 14.
    Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667–78.CrossRefGoogle Scholar
  15. 15.
    Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, et al. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19:173–9.CrossRefGoogle Scholar
  16. 16.
    Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86:269–74.CrossRefGoogle Scholar
  17. 17.
    Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.CrossRefGoogle Scholar
  18. 18.
    Osumi T, Mori T, Fujita N, Saito AM, Nakazawa A, Tsurusawa M, et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer. 2016;63:1794–9.CrossRefGoogle Scholar
  19. 19.
    Anoop P, Sankpal S, Stiller C, Tewari S, Lancaster DL, Khabra K, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53:1882–8.CrossRefGoogle Scholar
  20. 20.
    Kim H, Park ES, Lee SH, Koo HH, Kim HS, Lyu CJ, et al. Clinical outcome of relapsed or refractory Burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat. 2014;46:358–65.CrossRefGoogle Scholar
  21. 21.
    Ladenstein R, Pearce R, Hartmann O, Patte C, Goldstone T, Philip T. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European lymphoma bone marrow transplantation registry. Blood. 1997;90:2921–30.Google Scholar
  22. 22.
    Jones RJ, Ambinder RF, Piantadosi S, Stantos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649–53.Google Scholar
  23. 23.
    Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, Nakamae H, Goto H, Eto T, Inoue M, Mori T, Terui K, Onizuka M, Koh K, Koga Y, Ichinohe T, Sawada A, Atsuta Y, Suzumiya J (2017) Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. Int J Hematol 105(3):369–376CrossRefGoogle Scholar
  24. 24.
    Rosenwald A, Ott G. Burkitt lymphoma versus diffuse large B-cell lymphoma. Ann Oncol. 2008;19:67–9.CrossRefGoogle Scholar
  25. 25.
    Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol. 2008;142:329–47.CrossRefGoogle Scholar
  26. 26.
    Fujita N, Kobayashi R, Takimoto T, Nakagawa A, Ueda K, Horibe K. Results of the Japan Association of Childhood Leukemia Study (JACLS) NHL-98 protocol for the treatment of B-cell non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia in childhood. Leuk Lymphoma. 2011;52:223–9.CrossRefGoogle Scholar
  27. 27.
    Cairo MS, Woessmann W, Pagel J. Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas. Biol Blood Marrow Transplant. 2013;19:38–43.CrossRefGoogle Scholar
  28. 28.
    Gopal AK, Guthrie KA, Rajendran J, Pagel JM, Oliveira G, Maloney DG, et al. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistant high-risk B-cell lymphoma. Blood. 2011;118:1132–9.CrossRefGoogle Scholar
  29. 29.
    Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016;127:2980–90.CrossRefGoogle Scholar
  30. 30.
    Lee S, Luo W, Shah T, Yin C, O’Connell T, Chung T, et al. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. Oncotarget. 2017;8:27839–53.Google Scholar
  31. 31.
    Grigg AP, Seymour JF. Graft versus Burkitt’s lymphoma effect after allogeneic marrow transplantation. Leuk Lymphoma. 2002;43:889–92.CrossRefGoogle Scholar
  32. 32.
    El-Mallawany NK, Cairo MS. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2015;13:113–23.Google Scholar
  33. 33.
    Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, et al. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia. 2015;29:448–55.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Naoto Fujita
    • 1
    Email author
  • Ryoji Kobayashi
    • 2
  • Yoshiko Atsuta
    • 3
  • Fuminori Iwasaki
    • 4
  • Junji Suzumiya
    • 5
  • Yoji Sasahara
    • 6
  • Masami Inoue
    • 7
  • Katsuyoshi Koh
    • 8
  • Tsukasa Hori
    • 9
  • Hiroaki Goto
    • 10
  • Tatsuo Ichinohe
    • 11
  • Yoshiko Hashii
    • 12
  • Koji Kato
    • 13
  • Ritsuro Suzuki
    • 14
  • Tetsuo Mitsui
    • 15
  1. 1.Department of PediatricsHiroshima Red Cross Hospital and Atomic-bomb Survivors HospitalHiroshimaJapan
  2. 2.Department of PediatricsSapporo Hokuyu HospitalSapporoJapan
  3. 3.Japanese Data Center for Hematopoietic Cell Transplantation, Department of Healthcare AdministrationNagoya University Graduate School of MedicineNagoyaJapan
  4. 4.Department of HematologyKanagawa Children’s Medical CenterYokohamaJapan
  5. 5.Department of Oncology/HematologyShimane University HospitalIzumoJapan
  6. 6.Department of PediatricsTohoku University Graduate School of MedicineSendaiJapan
  7. 7.Department of Hematology/OncologyOsaka Medical Center and Research Institute for Maternal and Child HealthOsakaJapan
  8. 8.Department of Hematology/OncologySaitama Children’s Medical CenterSaitamaJapan
  9. 9.Department of PediatricsSapporo Medical University School of MedicineSapporoJapan
  10. 10.Division of Hemato-Oncology/Regenerative MedicineKanagawa Children’s Medical CenterYokohamaJapan
  11. 11.Department of Hematology and Oncology, Research Institute for Radiation Biology and MedicineHiroshima UniversityHiroshimaJapan
  12. 12.Pediatrics, Osaka University Graduate School of MedicineOsakaJapan
  13. 13.Department of Hematology and Oncology, Children’s Medical CenterJapanese Red Cross Nagoya First HospitalNagoyaJapan
  14. 14.Department of Oncology and HematologyShimane University Hospital Cancer CenterIzumoJapan
  15. 15.Department of PediatricsYamagata University School of MedicineYamagataJapan

Personalised recommendations